<DOC>
	<DOCNO>NCT03015207</DOCNO>
	<brief_summary>This trial conduct The United States America . The aim trial investigate Safety , Tolerability Pharmacokinetics ( exposure trial drug body ) NNC0194-0499 Male Subjects Overweight Obesity .</brief_summary>
	<brief_title>First Human Dose Trial Investigating Safety , Tolerability Pharmacokinetics NNC0194-0499 Male Subjects With Overweight Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Male , age 22âˆ’55 year ( inclusive ) time sign informed consent Body mass index ( BMI ) 25.0 34.9 kg/m^2 ( inclusive ) . Overweight due excess adipose tissue , judge investigator Any concomitant illness disorder , investigator 's opinion might jeopardise subject 's safety compliance protocol Subjects age equal 40 year estimate 10year atherosclerotic cardiovascular disease ( ASCVD accord ACC/AHA ( American College Cardiology /American Heart Association ) guideline ) risk equal 5 % Male subject sexually abstinent surgically sterilise ( vasectomy ) sexually active female partner ( ) use highly effective method contraception ( condom spermicide ) combine highly effective method contraception nonpregnant female partner ( ) ( Pearl Index 1 % , implant , injectables , oral contraceptive , intrauterine device , diaphragm cervical cap+spermicide ) , and/or intend donate sperm period screening ( visit 1 ) 3 month follow administration investigational medical product Use prescription nonprescription medicinal product include herbal product nonroutine vitamin , within 2 week prior screen , exception occasional use acetaminophen , ibuprofen acetylsalicylic acid</criteria>
	<gender>Male</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>